AMAG Pharmaceuticals (AMAG)

[mlkrborn]

Euro marketing: $15
AMAG Pharma: Rienso (ferumoxytol) receives European Marketing Authorization for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; triggers $15 mln milestone payment to co (AMAG) 15.28 +0.84 : Co announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous iron therapy to treat iron deficiency anemia in adult patients with chronic kidney disease. The marketing authorization is valid in the current European Union Member States as well as in Iceland and Norway, and is based on data obtained from an extensive clinical development program. Takeda Pharmaceutical Company (TKPPY), AMAG's partner in Europe, plans to launch ferumoxytol in Europe under the brand name Rienso in 2012. The EU marketing authorization triggers a $15 million milestone payment to AMAG from Takeda; the first commercial sale of Rienso in Europe will trigger another $15 million milestone payment to AMAG. Additionally, AMAG is entitled to receive tiered, double-digit royalties on sales of Rienso in the licensed territories.